FDA approves new pancreatic cancer drug that could extend patients' lives
Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.
FIP XML/RSS/RDF Newsfeed Syndication https://freeinternetpress.com/rss.php
© 2026 FreeInternetPress.com
Free Internet Press is licensed under a Creative Commons Attribution 3.0 United States License. You may reuse or distribute original works on this site, with attribution per the above license. Any mirrored or quoted materials may be copyright their respective authors, publications, or outlets, as shown on their publication, indicated by the link in the news story. Such works are used under the fair use doctrine of United States copyright law. Should any materials be found overused or objectionable to the copyright holder, notification should be sent to [email protected], and the work will be removed and replaced with such notification.
Please email [email protected] with any questions.